Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Monday saw the release of JMP Securities' latest industry overview for the biotechnology sector, which highlighted key events from January 2025. The report noted a modest resurgence in the sector, ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Oil futures ended lower Friday, contributing to a loss for the week, though prices held on to a gain for the month as traders awaited a tariff decision by President Donald Trump on crude imports from ...

Amongst the flurry of corporate earnings and economy-shaking announcements from the newly elected U.S. administration, the U.S. IPO pipeline maintains its steady pace. This week, building materials ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

What especially shook investors was the prospect that China may have closed the tech gap with the United States in AI and especially DeepSeek’s claim that it developed R1 for just $5.6 million—a far ...

2-Year U.S. Treasury Note Continuous Contract $102.758-0.055-0.05% 5-Year U.S. Treasury Note Continuous Contract $106.391 0.000 0.00% 10-Year U.S. Treasury Note Continuous Contract $108.938 0.094 ...

Cystic fibrosis drug developer Sionna Therapeutics hopes to join the IPO wave started by Metsera and Maze Therapeutics last ...

2-Year U.S. Treasury Note Continuous Contract $102.879-0.016-0.02% 5-Year U.S. Treasury Note Continuous Contract $106.539-0.078-0.07% 10-Year U.S. Treasury Note Continuous Contract $109.031-0.203 ...